Over 67 million screenings – AstraZeneca’s ‘Healthy Heart Africa’ celebrates 10 years of transforming Noncommunicable Disease (NCD) care
Astrazeneca (www.astrazeneca.com) Flagship Health Equity Program – Healthy Heart Africa (HHA), marking its 10th anniversary, celebrates more than 67 million blood pressure screenings and takes a decade of action against noncommunicable diseases in Africa.
Hypertension is a major risk factor for cardiovascular disease and accounts for a large proportion of non-communicable diseases (NCD) deaths worldwide. In Africa, more than 27% of adults suffer from hypertension(1)far above the global average.
Since its launch, HHA has conducted over 67 million blood pressure tests, trained 11,700 health care workers and in Kenya, Ethiopia, Ghana, Ghana, Uganda, Côte d’Ivoire, Senegal, Senegal, Nigeria, Nigeria, Nigeria, Nigeria, Nigeria and Lanwang Da, Nigeria and Lanwanda, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, Ghana, more than 11,700 people have trained more than 1,550 medical institutions. Tanzania, including Zanzibar. These efforts greatly improve the chances of obtaining diagnosis and treatment of hypertension, thus saving countless lives.
Ruud Dobber, Executive Vice President and President, Biopharmaceutical Business Unit, Astrazeneca, “Healthy Heart Africa embodies AstraZeneca’s commitment to equitable health care. Over the past decade, we have empowered millions of people to manage their heart health. Now, we have expanded to cope with chronic conditions. Kidney disease ensures greater resilience in health systems across the continent.”
The program has begun to address chronic kidney disease (CKD), which is closely related to hypertension and affects 15.8% of Africans.(2) Early detection and management are crucial because CKD often progresses quietly. HHA is designed to improve the opportunity for timely diagnosis and treatment, thereby reducing the burden of disease throughout the community.
This commemoration lays the foundation for the upcoming NCD high-level meeting held by the World Health Organization(3)strengthen the urgency of collective action. One aspect of the program’s success is built on a strong partnership with government, NGOs and community leaders to engage in culturally tailored interventions.
Helen McGuire, head of the Path Global Program, added:
“It is really transformative to have a Healthy Heart Africa (HHA) program with AstraZeneca. It makes great sense to see the expansion and institutionalization of integrated and expanded NCD services, especially in countries like Ghana. Introducing NCD indicators into national health Information systems are a major milestone that allows better planning, resource allocation and outcome monitoring.”
The African Ministry of Health advocates that HHA integrates hypertensive care into national policies to ensure sustainability and local ownership.
Permanent Secretary Dr Diana Atwine Kanzira, Uganda Ministry of Health, said:
“In Uganda, our partnership with Healthy Africa helps strengthen our response to noncommunicable diseases (NCDs), a major health challenge across Africa. Through this collaboration, we have increased people’s risk factors Recognition, improves early detection, connects patients, and builds the capacity of healthcare workers. By integrating hypertension data into our national health systems and advancing digitalization, we are ensuring seamless patient pathways, enabling progress tracking and Provide life-saving care for our people.”
With its proven model – Healthy Heart Africa program aims to expand into new regions, integrate climate-rich healthcare solutions and prioritize early detection to prevent disease progression. Through this innovative partnership, the program is designed to provide care to those in the most need.
To learn more about this program, read our impact report link here (https://apo-opa.co/3qpqsjf).
(1) https://apo-opa.co/41Gyyny.
(2) https://apo-opa.co/4b7qzax
(3) https://apo-opa.co/4jrojxr
AstraZeneca data for submissions: Master Plan Numbers from 2014 to the end of December 2024
Distributed by Apo Group on behalf of Astrazeneca.
related:
Small road
Path is an international non-governmental organization dedicated to improving the health outcomes of vulnerable people around the world. Through innovation, partnerships and commitment to equity, Path responds to the urgent need to address global health challenges, including non-communicable diseases, maternal and child health, and infectious diseases. Learn more www.path.org.
AstraZeneca
AstraZeneca (LSE/Sto/Nasdaq:AZN) is a global, scientifically-led biopharmaceutical company focusing on the discovery, development and commercialization of prescription drugs in oncology, rare diseases and biopharmaceuticals, including cardiovascular , kidney, kidney, kidney and metabolism and breathing and breathing and respiration and immunology. Headquartered in Cambridge, UK, AstraZeneca operates in more than 100 countries, its innovative drugs are used by millions of patients around the world. Please visit Astrazeneca.com And follow the company on Twitter @AstraZeneca.
refer to
(1) https://apo-opa.co/41Gyyny.
(2) https://apo-opa.co/4b7qzax
(3) https://apo-opa.co/4jrojxr
AstraZeneca data for submissions: Master Plan Numbers from 2014 to the end of December 2024
